Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 219

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 219
---
on, voting as a single class. Accordingly, none of a stockholder’s failure to vote online or by proxy, a broker non-vote or an abstention will be considered a “vote cast,” and thus will have no effect on the outcome of the ParentCo Charter Proposal, the Incentive Plan Proposal, or the Adjournment Proposal.

The Business Combination Proposal is not conditioned on the approval of any other proposal. The Incentive Plan Proposal is conditioned on the approval of the Business Combination Proposal. The ParentCo Charter Proposal, the Advisory Charter Proposals and the Adjournment Proposal are not conditioned on the approval of any other proposal set forth in this proxy statement/prospectus. It is important for you to note that in the event the Business Combination Proposal does not receive the requisite vote for approval, then we will not consummate the Business Combination. If we do not consummate a business combination or amend the Iris Certificate of Incorporation by stockholder approval by March 31, 2025 (subject to an additional three month extension at the discretion of the Board), we will be required to dissolve and liquidate the Trust Account by returning the then remaining funds in such Trust Account to our public stockholders.

#### Recommendation to Iris Stockholders
The Iris Board believes that each of the Business Combination Proposal, the Nasdaq Proposal, the Incentive Plan Proposal, the ParentCo Charter Proposal, the Advisory Charter Proposals, the Election of Directors Proposal, and the Adjournment Proposal to be presented at the Special Meeting is fair to and in the best interests of us and our stockholders and unanimously recommends that our stockholders vote “

#### FOR
” each of the proposals.

When you consider the recommendation of the Iris Board in favor of approval of the Business Combination Proposal, you should keep in mind that our directors and officers have interests in the Business Combination that are different from or in addition to (or which may conflict with) your interests as a stockholder. For additional information, see the section entitled “ Proposal No. 1 — The Business Combination Proposal — Interests of Certain Persons in the Business Combination. ”

#### Broker Non-Votes and Abstentions
Under the rules of various national and regional securities exchanges, your broker, bank, or nominee cannot vote your shares with respect to non-discretionary matters unless you provide instructions on how to vote in accordance with the information and procedures provided to you by your broker, bank, or nominee. We believe the proposals presented to the stockholders will be considered non-discretionary